MedPacto Voluntarily Withdraws Trial of Bactosertib and Imatinib Combination Therapy
[Asia Economy Reporter Junho Hwang] MedPacto announced on the 23rd that it has voluntarily withdrawn the comparative trial of Vactosertib and Imatinib combination therapy versus Imatinib monotherapy in progressive desmoid tumors (aggressive fibromatosis) (MP-VAC-206). The company explained, "As we revised our strategy to focus our capabilities on clinical trials of cancer types that can be commercialized early, we have adjusted our portfolio regarding the Vactosertib clinical trial."
Hot Picks Today
"Buy on Black Monday"... Japan's Nomura Forecasts 590,000 for Samsung, 4 Million for SK hynix
- "Plunged During the War, Now Surging Again"... The Real Reason Behind the 6% One-Day Silver Market Rally [Weekend Money]
- [Revolutionary Guards Inc.]③Unyielding in External Wars for Profit... "Unlikely to Relinquish Hormuz"
- Experts Are Already Watching Closely..."Target Stock Price 970,000 Won" Now Only the Uptrend Remains [Weekend Money]
- "That? It's Already Stashed" Nightlife Scene Crosses the Line [ChwiYak Nation] ③
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
